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Postoperative nausea and vomiting (PONV) is a relatively common occurrence (20–30%) that delays discharge and, if persistent,
can lead to serious complications. The incidence of PONV is a function of patient characteristics, the type and duration of surgery,
the type of anesthesia, and the choice of pre-, intra-, and postoperative pharmacotherapy. There are no completely eﬀective
antiemetic agents for this condition, but recommendations for treatment strategies are separately available for pediatric and
adult patients. Left unclear is whether adolescents should be guided by the pediatric or the adult recommendations. We review
the developmental physiology of the relevant physiological factors (absorption, distribution, metabolism, and elimination). We
also review the clinical evidence regarding the safety and eﬃcacy of a ﬁxed-dose combination of ondansetron (4mg, i.v.) and
transdermal scopolamine (1.5mg).
1. Epidemiology of PONV in Adult and
PediatricPatients
Postoperative nausea and vomiting (PONV) is a challenging
condition with an overall incidence estimated to be around
20% to 30% [1]. With an estimated 46 million inpatient sur-
gical procedures performed in 2006 [2], that amounts to 9 to
13 million cases of inhospital PONV annually. The incidence
of PONV may be higher in the burgeoning area of outpatient
surgery. One study found that PONV occurs in up to 17%
of outpatients in ﬁrst 48 hours postsurgery compared to only
about 10% of inhospital patients who visit a postanesthesia
care unit (PACU) [3] .T h es a m ei n v e s t i g a t o r sd e t e r m i n e d
that PONV delayed patient’s discharge and lost revenue for
the facility [4].
The occurrence of PONV depends on many factors,
including those relating to the patient, for example, age,
gender,bodyweight,historyofmotionsickness,anxiety,gas-
troparesis, the underlying disease, type of surgery, and ane-
sthesia. Age has two aspects: PONV is more frequent in
pediatric patients with increasing age, that is, over the age
of three, but PONV is less frequent in adults with advancing
age [1, 5]. Persistent nausea and vomiting may result in
dehydration and electrolyte imbalance, and can increase
tension on suture lines. Persistent nausea and vomiting has
been associated with an increase in venous hypertension and
bleeding under skin ﬂaps. In patients with depressed res-
piration owing to anesthesia or postsurgical analgesics,
there is the possibility of inhaling vomit, which could
lead to pulmonary complications. PONV is associated with
signiﬁcant morbidity [6], sometimes leading to delayed dis-
charge or hospital readmission. Furthermore, patients ﬁnd
nausea and vomiting highly disagreeable and distressing.
In fact, the literature reports that patients regard PONV very
negatively [7, 8].2 Journal of Drug Delivery
The mechanisms behind PONV are the same in adults
and children [6]. The physiology of this protective reﬂex
involves several neurotransmitter systems, including do-
pamine, opioid, histamine, cannabinoid, muscarinic cho-
linergic, and 5-HT (5-hydroxytryptamine; serotonin rec-
eptors). The 5-HT3 subtype of the serotonin receptor
pathway plays a major role in the modulation of the PONV
reﬂex.Pharmacologicantagonistsofthe5-HT3receptorhave
antiemetic properties. Ondansetron (9-Methyl-3-[(2-me-
thyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4
(9H)-one), a selective high-aﬃnity competitive antagonist
of the 5-HT3 receptor, is a commonly used antiemetic for
PONV prophylaxis approved for use in children, and makes
no speciﬁc diﬀerentiations in pediatric dosing beyond
weight; doses are the same for adults and pediatric patients
40kg (88lb) or larger, regardless of age [9].
However, pediatric patients experience more complica-
tions in the PACU than adults [10]. In the pediatric popula-
tion, postoperative vomiting (POV) is more often evaluated
than PONV, because it is easier to quantify vomiting than
nausea among patients with limited verbal skills. Since
pediatricstudiesofveryyoungpatientsevaluatemainlyPOV,
the incidence of pediatric PONV is likely underestimated.
Nevertheless, the incidence of POV/PONV in young patients
is generally held to be about double that of the adult
population with overall incidences ranging from 8.9% to
42% and surgery-speciﬁc incidences that range from 9% to
80% [11, 12].
Among pediatric patients, one study found a lower rate
of POV among children less than three years of age (22–
40%) when compared to children over the age of three (42–
51%) [13]. While increasing age decreases the risk of POV in
adults [1, 5], the opposite is true in pediatric patients. POV
incidencesarelowestbelowagethreeandhighestintherange
of 11 to 14 years [12, 14].
Risk assessment tools exist for PONV in adults. Four
independent predictors have been identiﬁed (female gender,
nonsmoker, history of PONV, and postoperative opioids),
and the risk of PONV was 20% for one of these predictors,
40% for two, 60% for three, and 80% if all four were present
[15]. A limitation to this and other risk assessment models
is that they are designed to assess risk among patient groups
rather than individuals [16].
These risk assessment tools did not necessarily work well
for the full spectrum of pediatric patients; for example,
smoking is not applicable, gender does not appear to be
a risk factor in prepubescent children, and there are distinct
diﬀerences in children before and after age three with respect
to PONV. Thus, pediatric-speciﬁc risk factors have been
developed [17]. The risk factors for pediatric POV were
f o u n dt ob ea g eo v e r3y e a r s ,s t r a b i s m u ss u r g e r y( b u tn o t
other types of surgical procedures), duration of surgery over
30 minutes, and history of POV/PONV either in the patient
or his or her parents or siblings [18]. While there is little
literature available on genetic factors involved in pediatric
POV, one study found that monozygotic twins are more
likely to have similar POV responses than heterozygote twins
[19]. With one positive risk factor using this risk assessment
tool, the risk of POV is 10%; with two, the risk is 30%;
with three, the risk is 55%; when all four risk factors are
present, the risk is 70%. Eberhart and colleagues did not ﬁnd
certain conditions to be independent risk factors of pediatric
POV:thetypeofanesthesia(localorregional),intraoperative
opioids, postoperative opioids, and female gender [18].
One of the drawbacks to these ﬁrst attempts at pediatric
risk assessments for POV/PONV in children is the fact that
the pediatric population is not homogeneous. Age itself
is an independent risk factor (older pediatric patients are
more likely to have POV than those under three). Female
gender was not found to be an independent risk factor
unless it was paired with age older female pediatric patients
(≥11 years old) are more like their adult counterparts in
that female gender confers an independent risk factor [18].
Risk factors speciﬁcally for the adolescent patient population
have not been thoroughly studied. Expert opinion holds
that adolescent risk factors would include female gender,
nonsmokers, history of PONV and/or motion sickness, or
PONV in relatives. Notwithstanding the information on risk
stratiﬁcation, current practice has adapted a more liberal
policy of broad antiemetic prophylactic administration to
adolescent patients.
2. Adult andPediatricPatients: Current
Treatment Options
The Society for Ambulatory Anesthesia Guidelines recom-
mend these drugs for antiemetic prophylaxis in children:
dexamethasone, dimenhydrinate, dolasetron, droperidol,
granisetron, ondansetron, perphenazine, and tropisetron
[20]. Not all of these agents are approved by the FDA for
use in pediatric patients. Ondansetron is a 5-HT3 antagonist
and is the only such agent approved for POV prophylaxis in
pediatric patients under the age of one month [20]. A dosing
comparison derived from this evidence, available mainly in
the form of systematic reviews and randomized clinical trials
in the literature, demonstrates that dosing for larger children
in many cases corresponds to adult dose recommendations.
See Table 1.
Ondansetron is generally considered to be the ﬁrst-line
antiemetic for pediatric patients because of its favorable side
eﬀect proﬁle [11]. The lowest eﬀective dose in pediatric
patients was found to be 0.05mg/kg [21]. Several pediatric
ondansetron studies have conﬁrmed its safety and eﬀective-
ness in POV prophylaxis [22–27]. For adults, the ﬁxed dose
of ondansetron for PONV prophylaxis is 4mg IV [9]. The
same dose is recommended for a pediatric patient weighing
40kg (88lb.) or more. The Centers for Disease Control and
Prevention published weight-for-age charts for boys and
girls, capturing actual data for 2000, showing that for the
50th percentile, both boys and girls exceed the 88-lb cutoﬀ
by the age of 12. Data from those charts are summarized in
Table 2.
Furthermore, childhood obesity is on the rise, and the
age segment with the steepest increase in obesity is the 12-
to 19-year-old pediatric population [30]. Compared to data
collected from 1976 to 1980, obesity among 12- to 19-year-
olds rose from 5.0% to 17.6% in 2003–2006. (CorrespondingJournal of Drug Delivery 3
Table 1: Prophylactic antiemetic agents supported by medical evidence for use in pediatric and adult patients. The high end of the pediatric
range often overlaps or is equivalent to the recommended adult dose [20].
Drug Type of drug Pediatric dose Adult dose Comment
Dexamethasone Corticosteroid 150μg/kg up to 5mg 4-5mg Adult and pediatric doses overlap
Dimenhydrinate Antihistamine 0.5mg/kg up to 25mg 1mg/kg
Dolasetron 5-HT3 antagonist 350μg/kg up to 12.5mg 12.5mg Adult and pediatric doses overlap
Droperidol Antidopaminergic drug 10–15μg/kg up to 1.25mg 0.625–1.25mg Black box warnings, high risk of sedation
Granisetron 5-HT3 antagonist 40μg/kg up to 0.6mg 0.35–1.5mg Adult and pediatric doses overlap
Ondansetron 5-HT3 antagonist 50–100μg/kg up to 4mg 4mg Adult and pediatric doses overlap
Perphenazine Phenothiazine (antipsychotic) 70μg/kg up to 5mg NA Only oral formulation is available in USA
Tropisetron 5-HT3 antagonist 0.1mg/kg up to 2mg 2mg Adult and pediatric doses overlap
Table 2: Weight for age, 50th percentile, CDC data for 2000 [28,
29].
Age Boys Girls
10 72lb (33kg) 70lb (32kg)
12 92lb (42kg) 90lb (41kg)
15 136lb (62kg) 115lb (52kg)
17 142lb (65kg) 120lb (55kg)
o b e s i t yr a t e sf o ro t h e ra g er a n g e sa r e1 2 . 4 %f o r2 -t o5 - y e a r -
olds and 17.0% for 6- to 11-year-olds.)
Since the etiology of PONV in adults and children is
multifactorial, prophylactic monotherapy has been limited.
Recent consensus guidelines for the management of PONV
in adults recommend the combining of antiemetic agents in
moderate- to high-risk patients in order to eﬀectively avoid
PONV [20]. The combination of ondansetron and transder-
mal scopolamine may confer increased beneﬁts to patients
considered at moderate to high risk for PONV.
3. Adolescent Patients:
Physiological Considerations
Adolescence is deﬁned as the transitional stage in human
development from childhood to adulthood, which com-
mences around the age of 10 to 12. Puberty may be the most
signiﬁcant biologic occurrence during adolescence, which
involves a surge in hormone production and a cascade of
physical changes. Secondary sexual characteristics appear
and the child’s body develops into an adult body. Menarche,
which commonly occurs in USA girls between the ages of 11
and 13, can be inﬂuenced by other factors, including how
much relative body fat the girl has [31]. The percentage of
body fat is lower at age 20 than at both ages 10 and 40 [32].
Apaperonpharmacologicalresearchinpediatricsfoundthat
drug absorption, distribution, metabolism and elimination
found that neonates and babies diﬀered from adults but did
not draw such distinctions for older children [33].
Whereas there are substantial clinical trial data or good
practice guidelines for adult and pediatric use of drugs for
PONV, fewer data are available for the speciﬁc uses of these
drugsforPONVinadolescents.Intheabsenceofsuchdata,it
would seem reasonable to extrapolate from the information
available for pediatric use at one end and adult use at the
other end. However, any special physiology or pharmacology
that might be associated with adolescence should ﬁrst be
considered.
The relevant question is whether the adolescent wouldbe
an “outlier” in the extrapolation between pediatric and adult
response to drugs for PONV. This would occur if pharma-
cologic response is discordant in this age group, that is, if
therearedramaticdevelopmentaldiﬀerencesinpharmacoki-
netics or pharmacodynamics. There is no reason to suspect
any diﬀerence in pharmacodynamics. Potential diﬀerences
in pharmacokinetics would involve the drugs absorption,
distribution, metabolism, and elimination (ADME). The
ontogeny of these processes can be found in recent compre-
hensive reviews.
3.1. Absorption. Due to the relatively higher gastric pH in
neonates, absorption of acidic and basic compounds is
reduced and enhanced, respectively, and this can contribute
to serum concentrations of drugs that are either higher
or lower in neonates relative to older children and adults.
However, diﬀerences in the intestinal absorption physiology
of neonates (including higher gastric pH, prolonged gastric
emptying, irregular motility, and relatively smaller intestinal
surface area) that might aﬀect drug absorption characteris-
tics typically do not extend beyond the early months of life.
Maturation of the gastrointestinal tract is usually essentially
complete well before two years of age.
For the special case of transdermal absorption, the epi-
dermis is already well developed in the full-term neonate
and is similar to adult skin with respect to epidermal and
stratum corneum thickness; it is fully keratinized by one
week after birth [34–36]. The skin surface of neonates
is characteristically neutral or alkaline (pH 6.2–7.5), but
declines rapidly within the ﬁrst month of life to 5.0–5.5, the
range of older children and adults [37–39].
Transdermal absorption appears to be independent of
age. In an investigation of the properties of skins and ma-
tured skin equivalents from foreskin keratinocytes isolated
from newborns (2–5d), children (3–11yr), and adults (17–
58yr), the percutaneous absorption of hydrocortisone
through skins and matured skin equivalents did not vary
with age [40].
3.2. Distribution. The percentage of body fat and water from
birth to 40 years of age has been characterized [41]. The total4 Journal of Drug Delivery







Figure 1: Transdermal scopolamine patch is aﬃxed to skin, where it delivers a priming dose and then a slow release of scopolamine through
a special rate-controlling membrane.
body waterand extracellularwater remain relatively constant
from one to 40 years old. There is a sharp decrease in body
fatofboysatpuberty(toabout17%),butnosimilardecrease
in body fat of girls during this period (giving rise to an
approximately 1.5 times greater percentage body fat during
this period). The distribution of lipophilic compounds may
be decreased, and a smaller volume of distribution for
lipophilic compounds is expected in boys of this age group.
The physiological variables inﬂuencing plasma protein
binding in infancy and childhood compared to adult values
havebeenreported[42].Totalplasmaproteinconcentrations
are approximately 59g/L, whereas they are approximately
72g/L in adults. Fetal albumin has lower binding capacity
compared to mature plasma albumin, so plasma protein
bindingofacidiccompoundsisreducedinneonates.Binding
of basic compounds is also reduced in neonates because of
lower levels of plasma globulin and α1-acid glycoprotein.
However, plasma albumin levels, as well as total protein,
plasma globulin, free fatty acids, unconjugated bilirubin,
blood pH, and α1-acid glycoprotein, are essentially at adult
levels by one year of age [42–45]. Both ondansetron and
scopolamine have relatively low plasma protein binding.
3.3. Metabolism. CYP3A7 is a major cytochrome P450
isozyme expressed during the fetal period, but there is
arapidswitchtoCYP3A4perinatally.CYP2E1activitysurges
within hours after birth, followed closely by the onset
of CYP2D6 expression [46, 47]. CYP3A4, CYP2C9, and
CYP2C19 activities appear during the ﬁrst week of life [48,
49]. CYP1A2, the ﬁnal hepatic CYP to attain signiﬁcant
expression, does so before 6 months postnatal age [50, 51].
Less is known about the developmental pattern of
phase II metabolism (glucuronidation and other transferase
reactions). Morphine clearance reaches adult levels by three
years of age [52], suggesting that metabolism (via UGT2B7-
mediated glucuronidation) is matured by this time.
In general, the activity of most drug-metabolizing en-
zymes (both phase I and phase II), which is lower in the
neonate, attains adult levels by six to 12 months of age and
no later than three years of age [53].
3.4. Elimination. Renal blood ﬂow increases with age, reach-
ing adult rates by six months of age. Renal elimination of
drugs depends on glomerular ﬁltration rate (GFR), tubular
reabsorption, and tubular secretion. In full-term infants,
thereisamarkedincreaseinGFRintheﬁrsttwotothreedays
ofpostnatallife[54,55].AdultvaluesforGFRareattainedby
six to 12 months of age [55, 56].
The proximal convoluted tubules in a full-term infant
kidney are small in relation to the glomeruli, thus there is
decreasedtubulartransportofcompounds.Tubularfunction
matures at a slower rate than does glomerular function but
nevertheless attains adult values by three years old.
4. TransdermalScopolamine
Transdermal scopolamine is an anticholinergic agent which
is well absorbed percutaneously and is detected in plasma
within four hours after patch application behind the ear;
peak plasma concentrations occur within 24 hours in adults
[57]. It crosses the placenta and blood-brain barrier. Its half-
lifeafterpatchremovalis9.5hours,butit’seﬀectsmaypersist
a f t e rt h ep a t c hi sr e m o v e d .
Transdermal scopolamine is extensively metabolized in
the body and conjugated with less than 5% of the total dose
excreted unchanged in the urine. The absorption of oral
medications may be decreased by transdermal scopolamine
because of decreased gastric motility and delayed gastric
emptying. Transdermal scopolamine should be used with
caution with other drugs capable of causing central nervous
system (CNS) eﬀects (such as sedatives, tranquilizers, and
alcohol) because of the risk of additive CNS eﬀects (e.g.,
dizziness). Transdermal scopolamine should be used with
caution with other drugs that have anticholinergic eﬀects,
including other belladonna alkaloids, antihistamines, tri-
cyclic antidepressants, and muscle relaxants.
The transdermal patch delivery system contains 1.5mg
of scopolamine which is delivered over 72 hours in a con-
tinuous slow release through a controlling membrane. The
patch is designed so that an initial bolus of scopolamine
is administered upon application, followed by continuous
release of the drug. See Figure 1.
5. TransdermalScopolamine Studies
A recent randomized, double-blinded study of transdermal
scopolamine used as prophylaxis for PONV compared com-
bination therapy (4mg IV ondansetron plus transdermal
scopolamine patch) to ondansetron alone (4mg IV) in 620Journal of Drug Delivery 5
adult females considered at risk for PONV [58]. Patients
wereundergoingeitheroutpatientlaparoscopyorbreastaug-
mentation surgery. The study was placebo controlled, in
that some patients received a sham patch. Patients were
assessed at 24 and 48 hours for PONV. The combination
therapy of transdermalscopolamine andondansetron signif-
icantly reduced nausea and vomiting/retching compared to
ondansetron alone at 24 hours postsurgery. More patients in
thecombinationgroupthantheondansetron-onlygroupdid
not experience vomiting or retching and did not use rescue
medication (48% versus 39%, P<0.02). The number of
patients who had no nausea, no vomiting/retching, and no
rescue medication was also signiﬁcantly greater in the com-
bination therapy group compared to the ondansetron-only
group (35% versus 25%, P<0.01). The combination group
had a signiﬁcantly longer time to ﬁrst episode of nausea,
vomiting/retching, or rescue medication compared to the
ondansetron-only group (P<0.05). In addition, the cumu-
lative incidence of adverse events was signiﬁcantly lower
in the transdermal scopolamine plus ondansetron group
compared to the ondansetron-only group (36.7% versus
49%, P<0.01).
6. Off-Label Studies of Transdermal
Scopolamine inPediatricPatients
A randomized study of 40 pediatric patients (ages 6 to 14
years) undergoing abdominal surgery under general anes-
thesia with extradural block received either transdermal
scopolamine (140μg loading dose followed by 5μg/h) or
placebo for the duration of time the child was kept on
patient-controlled analgesia (PCA) using morphine [59].
The patients in the transdermal scopolamine group had
signiﬁcantly less incidence of PONV (P<0.001) versus the
controlgroupintheﬁrst48hoursaftersurgery.Sideeﬀectsin
the treated group occurred more often: sedation (P<0.02)
and dry mouth (P<0.01) were most commonly reported.
There are no other randomized clinical trials of trans-
dermal scopolamine in the adolescent population. However,
there is a study (n = 54) of patients aged one to 11 years
undergoing strabismus surgery who were randomized to
receiveatransdermalscopolaminepatchorplacebopatchfor
PONV prophylaxis [60]. The rate of PONV was signiﬁcantly
lower in the transdermal scopolamine patch group than
placebo (16% versus 48%, P<0.05). Of vomiting episodes
thatdidoccur,onlysingleeventsoccurredinthetransdermal
scopolamine group, while control patients had a median of
3.1 episodes each (range: 1 to 7). No patients in either group
complained of any side eﬀects. This particular study reduced
dosage in some patients by cutting the patch; this study
included no patients over the age of 11.
7. Conclusions
The incidence of PONV among adolescent patients is as
high as—and likely higher than—the incidence of PONV
among adults. However, there are not many FDA-approved
treatment options to address adolescent PONV and those
that do usually stipulate doses based on body weight typical
of patients in the age range of 12 to 17 years (40kg or 88lb).
Although there are very few oﬀ-label studies of transdermal
scopolamine in the pediatric population, two have been
cited here that found transdermal scopolamine safe and ef-
fective [59, 60]. Based on body weight dosing information
for ondansetron and the fact that ADME parameters for
adolescents are similar to those of adults, it seems reasonable
that adolescent patients, ages 12 to 17 years, may derive
similar safety and eﬃcacy beneﬁts from the addition of a
1.5mg transdermal scopolamine patch to a 4mg IV dose of
ondansetron for the prevention of PONV.
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